BAXTER INTERNATIONAL INC
boothcheck covers BAXTER INTERNATIONAL INC (BAX) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Two self-identified problems explain most of the damage: the Novum large-volume infusion pump is under a ⟦"voluntary ship and installation hold in the U.S. and Canada, which remains ongoing"⟧, and U.S. IV solutions demand has fallen because hospitals adopted ⟦"fluid conservation practices embedded with clinical practice changes"⟧. • Operating margin is the entire verdict: about 4.4 percent on the trailing year against roughly 13.5 percent on the company's own through-cycle economics, and every
Is BAX overvalued? See what's priced in →
638 institutional managers reported holding BAX in 13F filings for the quarter ended 2026-03-31. 69 opened new positions that quarter. Held by BlackRock, Pzena Investment Management, Vanguard Group, among others. On the short side, 41.7M shares were sold short as of the 2026-06-15 count, about 8% of shares outstanding (6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BAX's share count grew 2.4% over the past five years even with $67.00M spent on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting); the current rate is $0.52 a share annually. Cash returned over the past three years: $1.24B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at BAX over the trailing three years. Absence is a fact about the company, not a signal. 24 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BAX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-28 | -4.0% | -19.7% |
| 2023-11-03 | +3.6% | +15.3% |
| 2024-02-09 | +0.4% | +2.0% |
| 2024-05-03 | -8.6% | -5.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BAX's latest 8-K filings: 2026-08-19 (items 5.02, 7.01, 9.01); 2026-08-18 (items 1.01, 8.01, 9.01); 2026-08-04 (items 5.02); 2026-08-04 (items 8.01, 9.01); 2026-07-30 (items 2.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.